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Pulmonary Medicine deals with the diseases of the respiratory tract and respiratory disease. It is called chest medicine and 
respiratory medicine in some countries and areas. Pulmonology is 
generally considered a branch of internal medicine. Chest medicine 
is not a specialty in itself but is an inclusive term which pertains to 
the treatment of diseases of the chest and contains the fields of 
pulmonology, thoracic surgery, and intensive care medicine. Effective 
disease treatment physician specializing in this area are called 
Pulmonologists.
The Journal of Pulmonary & Respiratory Medicine under open 
access category aims to advance our understanding of the diagnosis 
and treatment of lung diseases, as well as secondary prevention 
(Tuberculosis). The Journal of Pulmonary & Respiratory Medicine 
is an international, peer-reviewed journal, publishing an overview of 
Pulmonary Medicine which includes the contents geared towards the 
fields of pulmonology, thoracic surgery, and intensive care medicine.
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Abstract
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, fatal form of diffuse interstitial lung disease, which 
is associated with substantial mortality and morbidity. Lung transplantation has become one of the treatments of 
choice for patients with advanced IPF and has shown a 75% reduction in risk of death compared with patients who 
remained on the waiting list. Patients undergoing lung transplantation are required to participate in preoperative and 
postoperative pulmonary rehabilitation. This case report describes palliative and end of life care in a patient with end 
stage pulmonary fibrosis listed for lung transplantation and discusses the transition from curative restorative care and 
palliative care to end of life care. The goals of care of patients waiting for lung transplantation should be reviewed 
regularly and clarified as the clinical condition of the patient changes. End of life care should not only be considered 
in terminally ill patients or patients who do not fulfil the criteria for lung transplantation, but should also be raised with 
patients on the lung transplant waiting list. The goal of palliative care is to “enhance quality of life for patient and family, 
optimize function, and help with decision making” and thus it can be delivered concurrently with life prolonging care.
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Introduction
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, 
fatal form of diffuse interstitial lung disease, which is associated with 
substantial mortality and morbidity [1]. The mean survival time for 
patients diagnosed with IPF is 2.5– 3.5 years. The disease is usually 
characterized by gradual onset of symptoms, with dyspnea being the 
most common and disabling symptom. 
Risk factors associated with disease development include smoking 
cigarettes, drug exposure, chronic aspiration pneumonia, infectious 
agents and genetic predisposition.1The management of IPF requires a 
methodical approach with regular evaluations and the implementation 
of pharmacological and non-pharmacological treatment strategies [1]. 
Anti-inflammatory treatments such as corticosteroids and azathioprine 
have been shown to be useful [2], however, disease progression usually 
occurs. Lung transplantation has become one of the treatments of 
choice for patients with advanced IPF [3]. However, patients with IPF 
are likely to be elderly with multiple medical co-morbidities that may 
preclude them from lung transplantation. IPF accounts for nearly 30% 
of lung transplantation procedures performed worldwide [4]. Patients 
with IPF who received a lung transplant show a 75% reduction in risk 
of death compared with patients who remain on the waiting list [5]. 
The chance of death while waiting for lung transplantation is greater 
for patients with IPF compared with cystic fibrosis and emphysema 
[6]. Because of the risk of peri operative morbidity and mortality, it is 
essential to weigh expected survival benefit with gain in quality of life 
for any candidate waiting for lung transplantation. 
Patients undergoing lung transplantation are required to participate 
in preoperative and postoperative pulmonary rehabilitation. This will 
help physicians to select appropriate surgical candidates, and also 
prepare the patients for the physical and psychological stress of surgery 
[7]. Palliative care originated as end of life care in the 1960s. At that 
time, it focused on providing control of symptoms and psychosocial 
and family support during the terminal phase of a serious life limiting 
disease. Since then its meaning and scope of practice has expanded far 
beyond its roots. According to the American Academy of Hospice and 
Palliative Medicine, the goal of palliative care is to “enhance quality of 
life for patient and family, optimize function, and help with decision 
making” and thus it can be delivered concurrently with life prolonging 
care [8]. World Health Organization (WHO) has given a broader 
definition, which states “Palliative care is an approach that improves 
quality of life for patients and their families facing problems associated 
with a life threatening illness. This is provided through the prevention 
and relief of suffering by means of early identification, accurate 
assessment and treatment of pain and other problems, physical, 
psychosocial and spiritual” [9]. 
The aim of this case report is to describe palliative and end of 
life care in a patient with end stage pulmonary fibrosis listed for lung 
transplantation and to discuss the transition from curative restorative 
care and palliative care to end of life care. It also highlights a need for 
improved collaboration between palliative care and respiratory team in 
order to work in a more integrated fashion.
Case Report
The patient, a 54 year old woman, was diagnosed with idiopathic 
pulmonary fibrosis in 2000. Her past medical history was notable for 
obesity, gastro oesophageal reflux disease and right knee replacement. 
She had never smoked and only had a moderate alcohol intake on 
weekends. She had worked in an aluminium factory as a process 
worker for fifteen years, and retired in 2009. She had been independent 
with activities of daily living until a few months before her final 
hospitalization.
Her disease trajectory was characterized by breathlessness, 
necessitating long-term ambulatory oxygen therapy and frequent 
admissions to hospital for exacerbations of lung fibrosis, particularly in 
the last six months of her life. Her exercise tolerance deteriorated and 
became limited to 100 metres. For many years she has been treated with 
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variable doses of prednisolone and azathioprine. She was assessed for 
transplantation eight months prior to her death and listed on the active 
transplant list four months before death.
Her final admission occurred to an acute care tertiary hospital 
in the thoracic ward for the management of community acquired 
pneumonia, complicated by type two respiratory failures. Type II 
respiratory failure is defined as PaCO2 higher than 50 mm Hg. Just prior 
to this admission her exercise capacity had became limited to 20-30 
metres. Due to persistent and significant respiratory failure, she became 
bed bound and dependent on non-invasive ventilation using bi-level 
positive airway pressure (BiPAP). She was unable to participate with 
physiotherapy, which was a necessary component of the preoperative 
phase of lung transplantation.
She was referred to the palliative care service by the thoracic 
team two weeks into her final admission for assistance with complex 
multiple symptom management, and anticipating discharge, for 
access to community supports. She was commenced on sustained 
release morphine (Kapanol) 10 mg daily, Morphine syrup 2-3 mg 
prn and clonazepam drops sublingually as required with reasonable 
improvement in subjective dyspnea.
This admission was further complicated by hospital acquired 
pneumonia and a further worsening of respiratory failure. She appeared 
to have fears of impending death and voiced a sense of “giving up.” Hope 
appeared to be a strong persisting theme in her coping strategy – a hope 
for lung transplantation and resumption of a “normal life.” She denied 
any ongoing depressive and anxiety symptoms and continued to receive 
psychosocial and emotional support from the ward social worker and 
the palliative care team. Conversations with her and her family about 
advance care planning had clarified that she would not receive cardio 
pulmonary resuscitation or invasive ventilation; although active ward 
measures and non invasive ventilation were still considered as part of 
her care plans in the event of a rapid deterioration.
Opioid administration for dyspnea was limited due to concerns of 
the treating thoracic team about opioid tolerance. Concerns regarding 
respiratory depression from opioids were also raised by the thoracic 
team as it was feared this may result in invasive ventilation, a relative 
contraindication for lung transplantation. The palliative care team 
attempted to educate the thoracic team about the use of opioids and 
the evidence that supports use for dyspnea. Her condition continued to 
deteriorate; the possibility of lung transplantation became increasingly 
unlikely. There were tensions between the desire of the clinical team to 
provide good symptom control, particularly relief of breathlessness, and 
the potential to further limit the opportunity for transplantation. The 
balance between the restorative curative care and palliative approach 
was a major challenge for the patient, family and health providers. 
Although progressive deterioration of her medical condition was well 
established and acknowledged by the treating team, the focus of care 
was on lung transplantation. It was extremely difficult for the patient 
to accept her unpromising situation after many months of “fighting” 
for lung transplantation. She was hopeful of resuming a normal life 
and had difficulty accepting that her illness was terminal. She and her 
family were prepared to accept any treatment that might allow her to 
receive lung transplantation. These optimistic goals of care appeared 
to be her major coping mechanism, despite awareness of her continued 
deterioration and poor prognosis. She remained very hopeful of lung 
transplantation up until the day prior to her death.
After six weeks of hospitalization and three weeks of continuous 
deterioration, the focus of her care had clearly changed from curative 
to completely palliative. She realised that lung transplantation was 
not a viable option and she continued to experience overwhelming 
breathlessness and distress. . A continuous subcutaneous infusion 
of low dose morphine and midazolam was commenced to assist her 
symptoms. She died peacefully in the hospital in the presence of her 
family and close friends within 24 hours.
Discussion
This case report highlights barriers to the provision of optimal 
palliative care, delaying the process of advance care planning, and 
difficulty balancing the curative restorative care and palliative care to 
improved quality of life and quality of dying [10].
Over the past two decades, lung transplantation has been 
recognized to offer significant improvement in survival and quality 
of life. However, the long term success in achieving these outcomes is 
limited primarily because of the development of chronic lung rejection 
and the adverse effects of immunosuppression [11].
In this case one of the barriers to providing optimal palliative care 
was the patient remaining on the active transplant list even when she 
had progressive deterioration. This delayed the discussion of end of 
life care and optimal management of her symptoms, as the patient was 
frightened that she might be abandoned by the lung transplant team. 
Despite remaining on an active transplant list, quality of symptom 
control should not be compromised. Another barrier was the restricted 
use of opioids, when this had certainly helped dyspnea. There was 
concern from the respiratory team that excessive opioid administration 
leading to tolerance and respiratory depression may result in invasive 
ventilation, a relative contra indication for lung transplantation. 
An unrealistic patient expectation about her long term prognosis 
and survival was another barrier for optimal palliative care. Fear of 
destroying the patient’s hope of “new life” also affected the quality 
of care provided in the terminal phase of illness. All these barriers 
to optimal palliative care of lung transplant have been described by 
Colman et al. [12].
Historically, opioids have been used since the 19th century to relieve 
dyspnea. Opioids were often helpful in relieving breathlessness in 
advanced respiratory failure. The effectiveness of opioids in treating 
dyspnea in cancer and COPD patients has been well established [13,14], 
but they were disappointingly underused. A fear of causing respiratory 
depression was not found by Bruera et al. [13]. 
As the patient and her family had a persistent hope for 
transplantation, the discussion of end of life care and patient preferences 
had not been initiated in a timely manner. Ideally, an early discussion of 
treatment preferences of patients with a life limiting disease is a key for 
the provision of optimal end of life care.This patient was first referred 
to palliative care four weeks before she died, when her poor respiratory 
function had severely reduced her quality of life. In this case delayed 
referral to the palliative care service had hindered the timely discussion 
of advance care planning. Ironically, the primary goal of care was to 
maintain patient existence (or well being), so that she could remain 
listed for lung transplantation. There were ample opportunities for the 
clinical team to initiate timely advance care planning discussions while 
pursuing transplantation.
Perhaps despite there being events that might have been anticipated 
and other unexpected medical changes, there was insufficient dialogue 
and documentation with her and her family to clarify the goals of 
care and allow a decision about possibly being removed from the 
transplantation list and discussion about how this final phase of her life 
might be managed. Even in the last two weeks of her life a discussion 
about advance care planning did not occur, as there was a ‘hope’ for 
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cure – i.e. transplantation, by the treating medical team, the family and 
the patient herself.
At times, it is nearly impossible to predict when death will occur or 
what medical event will lead to a patient’s death. Therefore it is important 
to have ongoing review of the patient’s medical condition and advance 
care planning including review of the patient’s treatment preferences. 
This enables the physician to set realistic goals of care which in turn may 
minimize inconsistencies in management, at the same time ensuring 
that the patient and their family’s wishes are respected. One should 
emphasise that the treatment does not stop during the terminal phase 
of the disease; instead the primary aim will be to alleviate unpleasant 
symptoms. There is also the opportunity for the patient and family to 
prepare for death, and time for important decisions to be made such as 
putting affairs in order and planning a funeral [15]. 
End of life care should not only be discussed with terminally ill 
patients or patients who do not fulfil the criteria for lung transplantation, 
but should also be raised with patients on the lung transplant waiting 
list.15Many health professionals recognize the importance of having 
discussions about future needs and plans, although uncertainties 
exist about the timing of, and who in the health team, should have the 
responsibility for these discussions [16]. In this case choosing the right 
moment to discontinue curative care and offer only end of life care was 
a great challenge and therefore, it was reasonable to discuss the patient’s 
preferences for end of life care earlier in the course of her illness, even 
before her respiratory function was compromised and she became bed 
bound.
When there is still hope for cure and a better outlook, palliative 
care planning is often perceived as contradictory to life prolonging 
treatment. The dual objectives of maintaining hope for transplantation 
whilst simultaneously preparing for the end of life was a great challenge 
for this patient, family and her care providers. A decision to forgo life 
prolonging medical interventions, including BiPAP, would have been 
made by balancing their potential benefits and burdens.
For patients on the lung transplantation list, the goal is to keep the 
patient as well as possible until potential donor organs can be found. 
Given this goal, more aggressive therapeutic options including invasive 
ventilation, intensive care, enteral feeding, and indwelling catheters 
are appropriate. However, when there is discussion of potential lung 
transplantation in the patients whose pulmonary function continues to 
deteriorate despite maximum medical therapy, issues of prognosis, risk 
of dying, the potential role and limitations of transplantation, the role of 
palliative care and the patient’s wishes should be raised.
For patients unsuitable for lung transplantation, a planned 
approach should occur whereby medical therapy for chronic lung 
diseases continues with an increasing focus on palliation. As palliative 
care becomes the main focus, the aim should be to maximize symptom 
relief and quality of life whilst accepting that progressive deterioration 
is inevitable. In this particular patient’s care, communication between 
the transplant and palliative care team could have been improved. 
Through improved communication between providers, realistic goals 
of care are encouraged, whilst the patient and their family’s hopes and 
wishes are maintained. 
Conclusion
IPF is a chronic, relentlessly progressive fibrotic disorder associated 
with substantial mortality and morbidity. Not all patients listed for 
transplantation will receive a transplant; 50% of patients will die 
waiting, and for recipients, the life expectancy remains at three to five 
years. The dual objectives of maintaining hope for transplantation 
whilst simultaneously preparing for the end of life is a great challenge. 
In this case despite progressive deterioration, ironically the patient was 
given hope of lung transplantation until the last day of her life. This 
resulted insub-optimal end of life care, which was further complicated 
by the conflicting needs of preparation for possible transplantation and 
simultaneously optimizing possible end of life care.
Palliative care can be offered concurrently with curative restorative 
care and the intensity of both cares should be titrated to the needs of the 
patient and family. In order to achieve the best pre transplant care, it is 
reasonable to provide the best curative and restorative care, however 
this approach should not preclude clinicians from early and regular 
dialogue with the patients and their families to ensure that informed 
decisions are made on the basis of the benefits and burdens of treatment 
options as medical conditions change.
In conclusion, the continued aggressive hope for lung 
transplantation denied this woman the opportunity to receive adequate 
symptom control and to prepare for the end of her life. Physicians are 
responsible to timely initiate the discussion of advance care planning 
and set realistic goals of care earlier in the course of illness. This could 
potentially improve the overall quality of medical and palliative care.
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